Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Sauter KA, Melton-Celsa AR, Larkin K, Troxell ML, O'Brien AD, Magun BE.

Infect Immun. 2008 Oct;76(10):4469-78. doi: 10.1128/IAI.00592-08. Epub 2008 Aug 11.

2.

Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.

Melton-Celsa AR, Carvalho HM, Thuning-Roberson C, O'Brien AD.

Clin Vaccine Immunol. 2015 Apr;22(4):448-55. doi: 10.1128/CVI.00022-15. Epub 2015 Feb 25.

3.

A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease.

Keepers TR, Psotka MA, Gross LK, Obrig TG.

J Am Soc Nephrol. 2006 Dec;17(12):3404-14. Epub 2006 Nov 2.

4.

Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2002 Feb;70(2):612-9.

5.

Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodies.

Cheng LW, Henderson TD, Patfield S, Stanker LH, He X.

Toxins (Basel). 2013 Oct 22;5(10):1845-58. doi: 10.3390/toxins5101845.

6.

Protection of mice against Shiga toxin 2 (Stx2)-associated damage by maternal immunization with a Brucella lumazine synthase-Stx2 B subunit chimera.

Mejias MP, Cabrera G, Fernández-Brando RJ, Baschkier A, Ghersi G, Abrey-Recalde MJ, Miliwebsky E, Meiss R, Goldbaum F, Zylberman V, Rivas M, Palermo MS.

Infect Immun. 2014 Apr;82(4):1491-9. doi: 10.1128/IAI.00027-14. Epub 2014 Jan 13.

7.

Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia.

Fernandez GC, Lopez MF, Gomez SA, Ramos MV, Bentancor LV, Fernandez-Brando RJ, Landoni VI, Dran GI, Meiss R, Isturiz MA, Palermo MS.

Clin Exp Immunol. 2006 Oct;146(1):76-84.

8.

Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.

Kim SH, Lee YH, Lee SH, Lee SR, Huh JW, Kim SU, Chang KT.

FEMS Immunol Med Microbiol. 2011 Dec;63(3):427-34. doi: 10.1111/j.1574-695X.2011.00869.x. Epub 2011 Oct 4.

9.

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.

Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C.

J Immunol. 2011 Jul 1;187(1):172-80. doi: 10.4049/jimmunol.1100491. Epub 2011 Jun 3.

10.

Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.

Ozaki M, Kang Y, Tan YS, Pavlov VI, Liu B, Boyle DC, Kushak RI, Skjoedt MO, Grabowski EF, Taira Y, Stahl GL.

Kidney Int. 2016 Oct;90(4):774-82. doi: 10.1016/j.kint.2016.05.011. Epub 2016 Jul 1.

11.

Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.

Ludwig K, Sarkim V, Bitzan M, Karmali MA, Bobrowski C, Ruder H, Laufs R, Sobottka I, Petric M, Karch H, Müller-Wiefel DE.

J Clin Microbiol. 2002 May;40(5):1773-82.

12.

Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.

Guirro M, Piazza RM, de Souza RL, Guth BE.

BMC Infect Dis. 2014 Jun 11;14:320. doi: 10.1186/1471-2334-14-320.

13.

Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.

Zoja C, Locatelli M, Pagani C, Corna D, Zanchi C, Isermann B, Remuzzi G, Conway EM, Noris M.

J Immunol. 2012 Oct 1;189(7):3661-8. Epub 2012 Aug 31.

14.

Compensatory renal growth protects mice against Shiga toxin 2-induced toxicity.

Camerano GV, Bustuoabad OD, Meiss RP, Gómez SA, Fernández GC, Isturiz MA, Palermo MS, Dran GI.

Pediatr Nephrol. 2006 Aug;21(8):1082-92. Epub 2006 May 16.

PMID:
16703367
15.

Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome.

Gómez SA, Fernández GC, Vanzulli S, Dran G, Rubel C, Berki T, Isturiz MA, Palermo MS.

Clin Exp Immunol. 2003 Feb;131(2):217-24.

16.

Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice.

Sheoran A, Jeong KI, Mukherjee J, Wiffin A, Singh P, Tzipori S.

BMC Immunol. 2012 Jun 1;13:27. doi: 10.1186/1471-2172-13-27.

17.

Promoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2.

Bentancor LV, Mejías MP, Pinto A, Bilen MF, Meiss R, Rodriguez-Galán MC, Baez N, Pedrotti LP, Goldstein J, Ghiringhelli PD, Palermo MS.

MBio. 2013 Oct 1;4(5):e00501-13. doi: 10.1128/mBio.00501-13.

18.

Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, Taylor FB.

Pediatr Nephrol. 2003 Feb;18(2):92-6. Epub 2003 Jan 10.

PMID:
12579394
19.

Chemokine receptor CCR1 disruption limits renal damage in a murine model of hemolytic uremic syndrome.

Ramos MV, Auvynet C, Poupel L, Rodero M, Mejias MP, Panek CA, Vanzulli S, Combadiere C, Palermo M.

Am J Pathol. 2012 Mar;180(3):1040-8. doi: 10.1016/j.ajpath.2011.11.011. Epub 2011 Dec 25.

PMID:
22203055
20.

Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS).

Mejias MP, Fernandez-Brando RJ, Ramos MV, Abrey-Recalde MJ, Zotta E, Meiss R, Palermo MS.

Curr Pharm Des. 2016;22(34):5294-5299.

PMID:
27356777

Supplemental Content

Support Center